Troglitazone

Troglitazone
Clinical data
Trade names	Rezulin, Resulin, Romozin, Noscal
Routes of; administration	By mouth (tablets)
ATC code	A10BG01 (WHO) ;
Legal status
Legal status	Production and promotion ceased;
Pharmacokinetic data
Elimination half-life	16–34 hours
Identifiers
	IUPAC name (RS)-5-(4-[(6-hydroxy-2,5,7,8-tetramethylchroman-2-yl)methoxy]benzyl)thiazolidine-2,4-dione;
CAS Number	97322-87-7 ;
PubChem CID	5591;
IUPHAR/BPS	2693;
DrugBank	DB00197 ;
ChemSpider	5389 ;
UNII	I66ZZ0ZN0E;
KEGG	D00395 ;
ChEBI	CHEBI:9753 ;
ChEMBL	ChEMBL408 ;
CompTox Dashboard (EPA)	DTXSID8023719 ;
Chemical and physical data
Formula	C24H27NO5S
Molar mass	441.54 g·mol−1
3D model (JSmol)	Interactive image;
Melting point	184 to 186 °C (363 to 367 °F)
	SMILES O=C1NC(=O)SC1Cc4ccc(OCC3(Oc2c(c(c(O)c(c2CC3)C)C)C)C)cc4;
	InChI InChI=1S/C24H27NO5S/c1-13-14(2)21-18(15(3)20(13)26)9-10-24(4,30-21)12-29-17-7-5-16(6-8-17)11-19-22(27)25-23(28)31-19/h5-8,19,26H,9-12H2,1-4H3,(H,25,27,28) ; Key:GXPHKUHSUJUWKP-UHFFFAOYSA-N ;
	(what is this?) (verify)

Troglitazone is an antidiabetic and anti-inflammatory drug, and a member of the drug class of the thiazolidinediones. It was prescribed for people with diabetes mellitus type 2.^[1]

It was patented in 1983 and approved for medical use in 1997.^[2] It was subsequently withdrawn.

^ Fisher L (4 November 1997). "Adverse Diabetes Drug News Sends Warner-Lambert Down". The New York Times. Retrieved 12 December 2012.
^ Fischer J, Ganellin CR (2006). Analogue-based Drug Discovery. John Wiley & Sons. p. 450. ISBN 9783527607495.